Timing hypothesis for postmenopausal hormone therapy: Its origin, current status, and future

Menopause

Volumn 20, Issue 3, 2013, Pages 342-353

  Clarkson, Thomas B ^a   Meléndez, Giselle C ^a   Appt, Susan E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Hormone therapy; Timing hypothesis

Indexed keywords

CONJUGATED ESTROGEN; GELATINASE A; GELATINASE B; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

BREAST CANCER; COLORECTAL CANCER; CONFIDENCE INTERVAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; ESTROGEN THERAPY; FEMALE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LITERATURE; MENOPAUSE; NONHUMAN; OBSERVATIONAL STUDY; OVARIECTOMY; POSTMENOPAUSAL HORMONE THERAPY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ADULT; ANIMALS; CORONARY ARTERY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; WOMEN'S HEALTH;

EID: 84874779493     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e3182843aad     Document Type: Review

References (70)

1. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75: 1102-1109.
2. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117: 1016-1037.
3. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313: 1044-1049.
4. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133: 933-941.
5. Sullivan JM, Vander ZR, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990;150: 2557-2562.
6. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343: 522-529.
7. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349: 535-545.
8. Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation 2001;104: 2256-2259.
9. Clarkson TB. The new conundrum: do estrogens have any cardiovascular benefits? Int J Fertil Womens Med 2002;47: 61-68.
10. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-333.
11. Karas RH, Clarkson TB. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med 2003;10: 8-12.
12. Williams JK, Anthony MS, Honore EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995;15: 827-836.
13. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007;14: 373-384.
14. Anthony MS, Clarkson TB. Does extent of pretreatment atherosclerosis influence the effects of conjugated equine estrogens on atherosclerosis pregression? J Am Coll Cardiol 2002;39: 248A.
15. McGill HC Jr, McMahan CA, Zieske AW, Malcom GT, Tracy RE, Strong JP. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 2001;103: 1546-1550.
16. McGill HC Jr, Stern MP. Sex and atherosclerosis. In: Paoletti R, Gotto AM Jr (Editors). Atherosclerosis Reviews, vol 4. New York, NY: Raven Press, 1979, 157-242.
17. Sutton-Tyrrell K, Lassila HC, Meilahn E, Bunker C, Matthews KA, Kuller LH. Carotid atherosclerosis in premenopausal and postmenopausal women and its association with risk factors measured after menopause. Stroke 1998;29: 1116-1121.
18. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. Atherosclerosis 2012;225: 180-186.
19. Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electronbeam computed tomography. Circulation 2000;101: 850-855.
20. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89: 1501-1510.
21. Wynne FL, Payne JA, Cain AE, Reckelhoff JF, Khalil RA. Age-related reduction in estrogen receptorYmediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. Hypertension 2004;43: 405-412.
22. Gavin KM, Seals DR, Silver AE, Moreau KL. Vascular endothelial estrogen receptor > is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women. J Clin Endocrinol Metab 2009;94: 3513-3520.
23. Novella S, Heras M, Hermenegildo C, Dantas AP. Effects of estrogen on vascular inflammation: a matter of timing. Arterioscler Thromb Vasc Biol 2012;32: 2035-2042.
24. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res 2011;109: 687-696.
25. Hermenegildo C, Garcia-Martinez MC, Tarin JJ, Cano A. Inhibition of low-density lipoprotein oxidation by the pure antiestrogens ICI 182780 and EM-652 (SCH 57068). Menopause 2002;9: 430-435.
26. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43: 985-991.
27. Kim J, Kim JY, Song KS, et al. Epigenetic changes in estrogen receptor A gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta 2007;1772: 72-80.
28. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010;30: 1282-1292.
29. Johnson JL, Jackson CL, Angelini GD, George SJ. Activation of matrixdegrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1998;18: 1707-1715.
30. Heo SH, Cho CH, Kim HO, et al. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol 2011;7: 69-76.
31. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348: 645-650.
32. Barrett-Connor E. Hormones and heart disease in women: the timing hypothesis. Am J Epidemiol 2007;166: 506-510.
33. Manson JE, Bassuk SS. Invited commentary: Hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am J Epidemiol 2007;166: 511-517.
34. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170: 12-23.
35. Banks E, Canfell K. Invited commentary: Hormone therapy risks and benefitsVthe Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 2009;170: 24-28.
36. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297: 1465-1477.
37. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135: 939-953.
38. Munir JA, Wu H, Bauer K, et al. The perimenopausal atherosclerosis transition: relationships between calcified and noncalcified coronary, aortic, and carotid atherosclerosis and risk factors and hormone levels. Menopause 2012;19: 10-15.
39. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med 2004;164: 482-484.
40. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15: 35-44.
41. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21: 363-366.
42. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19: 791-804.
43. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166: 357-365.
44. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356: 2591-2602.
45. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012;15: 217-228.
46. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009;119: 922-930.
47. Hodis HN, Mack WJ, Kono N, et al. Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial. Stroke 2011;42: 3168-3175.
48. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345: e6409.
49. Harman SM. New findings from the Kronos Early Prevention Study (KEEPS) randomized trial. The North American Menopause Society 23rd Annual Meeting, October 6, 2012.
50. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-A estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10: 1051-1057.
51. Appt SE, Clarkson TB, Lees CJ, Anthony MS. Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas 2006;55: 187-194.
52. Clarkson TB. Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis of postmenopausal monkeys. Menopause 2013;20: 274-281.
53. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab 2001;86: 5396-5404.
54. Wildman RP, Colvin AB, Powell LH, et al. Associations of endogenous sex hormones with the vasculature in menopausal women: the Study of Women's Health Across the Nation (SWAN). Menopause 2008;15: 414-421.
55. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Progression rates of carotid intima-media thickness and adventitial diameter during the menopausal transition. Menopause 2012;1: 8-14.
56. El Khoudary SR, Wildman RP, Matthews K, et al. Effect modification of obesity on associations between endogenous steroid sex hormones and arterial calcification in women at midlife. Menopause 2011;18: 906-914.
57. Johnson BD, Dwyer KM, Stanczyk FZ, et al. The relationship of menopausal status and rapid menopausal transition with carotid intima-media thickness progression in women: a report from the Los Angeles Atherosclerosis Study. J Clin Endocrinol Metab 2010;95: 4432-4440.
58. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006;113: 657-663.
59. Kazmierski M, Michalewska-Wludarczyk A, Krzych LJ. Intima-media thickness and flow-mediated dilatation in the diagnosis of coronary artery disease in perimenopausal women. Pol Arch Med Wewn 2010;120: 181-188.
60. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113: 664-670.
61. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flowmediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol 2008;51: 997-1002.
62. Moreau KL, Hildreth KL, Meditz AL, Deane KD, Kohrt WM. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab 2012;12: 4692-4700.
63. Gavin KM, Jankowski C, Kohrt WM, Stauffer BL, Seals DR, Moreau KL. Hysterectomy is associated with large artery stiffening in estrogendeficient postmenopausal women. Menopause 2012;19: 1000-1007.
64. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012;97: 1159-1168.
65. Santoro N, Randolph JF Jr. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am 2011;38: 455-466.
66. O'Connor KA, Ferrell RJ, Brindle E, et al. Total and unopposed estrogen exposure across stages of the transition to menopause. Cancer Epidemiol Biomarkers Prev 2009;18: 828-836.
67. Tepper PG, Randolph JF Jr, McConnell DS, et al. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women's Health Across the Nation (SWAN). J Clin Endocrinol Metab 2012;97: 2872-2880.
68. Ihionkhan CE, Chambliss KL, Gibson LL, Hahner LD, Mendelsohn ME, Shaul PW. Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ Res 2002;91: 814-820.
69. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002;89: 12E-17E.
70. Kaplan JR, Manuck SB, Anthony MS, Clarkson TB. Premenopausal social status and hormone exposure predict postmenopausal atherosclerosis in female monkeys. Obstet Gynecol 2002;99: 381-388.